Shawna Fury
Family · Davenport, IANPI 1942721584
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,492, 6.3 times the $237 reported in 2021. Among family clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$731
- Novo Nordisk$331
- Teva Pharmaceuticals USA, Inc.$296
- Alkermes, Inc.$295
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$261
- Neurocrine Biosciences, Inc.$180
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,583100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $731 |
| Novo Nordisk | 5 | $331 |
| Teva Pharmaceuticals USA, Inc. | 12 | $296 |
| Alkermes, Inc. | 18 | $295 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $261 |
| Neurocrine Biosciences, Inc. | 10 | $180 |
| Otsuka America Pharmaceutical, Inc. | 9 | $180 |
| Axsome Therapeutics, Inc. | 8 | $158 |
| Lundbeck LLC | 10 | $156 |
| Corium, LLC | 8 | $118 |
| Boehringer Ingelheim | 1 | $112 |
| Biogen | 1 | $104 |
| Vanda Pharmaceuticals Inc. | 3 | $84 |
| E.r. Squibb & Sons, L.L.C. | 4 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| Astellas Pharma US Inc | 1 | $52 |
| Indivior Inc. | 3 | $51 |
| USWM, LLC | 2 | $48 |
| Exact Sciences | 2 | $45 |
| Dexcom, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $35 |
| Gilead | 2 | $35 |
| Amgen | 2 | $27 |
| AstraZeneca | 2 | $27 |
| Almatica Pharma LLC | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,583 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 42 | $27,993 |
| JardianceEmpagliflozin | 24 | $26,903 |
| TrulicityDulaglutide | 28 | $26,891 |
| OzempicSemaglutide | 24 | $23,597 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $14,210 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $10,995 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $8,319 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,739 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $5,491 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 163 | $4,001 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $3,505 |
| Atorvastatin Calcium | 436 | $3,105 |
| Ventolin HfaAlbuterol Sulfate | 40 | $2,224 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $2,116 |
| Gabapentin | 128 | $1,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $112 | $26,90324 claims |
| Lilly USA, LLCTrulicity | $35 | $26,89128 claims |
| Novo NordiskOzempic | $331 | $23,59724 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $27 | $13,23137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.
Other family in Davenport
- Rebecca SolomonDavenport$11K
- Kimberly HurleyDavenport$6K
- Chelsea MausserDavenport$4K
- Amanda PetersonDavenport$4K
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.